Advances in leishmaniasis chemotherapy and new relevant patents

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 8, 2004, Pages 1113-1123

  Piñero, Jose E ^a   Jiménez, Ignacio A ^a   Valladares, Basilio ^a   Ravelo, Ángel G ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Chemotherapy; Drug discovery; Leishmaniasis

Indexed keywords

1 TETRALONE DERIVATIVE; 8 AMINOQUINOLINE DERIVATIVE; ACETOGENIN; ALKALOID DERIVATIVE; ALLOPURINOL; AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; AZITHROMYCIN; CHALCONE DERIVATIVE; COUMARIN DERIVATIVE; LACTONE DERIVATIVE; LIGNAN; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAMIDRONIC ACID; PAROMOMYCIN; PENTAMIDINE; PLACEBO; QUINONE DERIVATIVE; SAPONIN; SITAMAQUINE; STIBOGLUCONATE SODIUM; TERPENE DERIVATIVE; UNINDEXED DRUG; XANTHONE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; CALCIUM HOMEOSTASIS; CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HEART DISEASE; HUMAN; INHIBITION KINETICS; KIDNEY DISEASE; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA PANAMENSIS; LIPID METABOLISM; LIPOGENESIS; LIVER DYSFUNCTION; MEDICINAL PLANT; MOUSE; NONHUMAN; PANCREATITIS; PARASITOSIS; PATENT; REVIEW; SIGNAL TRANSDUCTION; SKIN LEISHMANIASIS; TERATOGENICITY; TREATMENT FAILURE; VISCERAL LEISHMANIASIS;

EID: 4344705219     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.8.1113     Document Type: Review

References (89)

1. DESJEUX P: Leishmaniasis: public health aspects and control. Clin. Dermatol. (1996) 14:417-423.
2. SHAW JJ: Taxonomy of the genus Leishmania: present and future trends and their implications. Mem. Inst. Oswaldo Cruz (1994) 89:471-478.
3. ASHFORD RW: The leishmaniases as model zoonoses. Ann. Trop. Med. Parasitol. (1997) 91:693-701.
4. BORST P, OUELLETTE M: New mechanisms of drug resistance in parasitic protozoa. Ann. Rev. Microbiol. (1995) 49:427-460.
5. GALLAGHER RB, MARX J, HINES PJ: Progress in parasitology. Science (1994) 264:1827.
6. HIRST SI, STAPLEY LA: Parasitology: the dawn of a new millennium. Parasitol. Today (2000) 16:1-3.
7. WORLD HEALTH ORGANIZATION: Annex 3: Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2001. In: The World Health Report. WHO, Geneva (2002):192-197.
8. SEAMAN J, MERCER AJ, SONDORP E: The epidemic of visceral leishmaniasis in western Upper Nile southern Sudan: course and impact from 1984 to 1994. Int. J. Epidemiol. (1996) 25:862-871.
9. HEWITT S, REYBURN H, ASHFORD R, ROWLAND M: Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: vertical distribution of cases in apartment blocks. Trans. Roy. Soc. Trop. Med. Hyg. (1998) 92:273-274.
10. GUERIN PJ, OLLIARO P, SUNDAR S et al.: Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. (2002) 2:494-501.
11. DAVIES CR, KAYE P, CROFT SL, SUNDAR S: Leishmaniasis: new approaches to disease control. Br. Med. J. (2003) 326:377-382.
12. WORLD HEALTH ORGANIZATION: WHO Model prescribing information: drugs used in parasitic diseases (2nd ed.). WHO, Geneva (1995).
13. BERMAN JD: Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. (1997) 24:684-703.
14. HERWALDT BL, BERMAN JD: Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg. (1992) 46:296-306.
15. MOORE E, O'FLAHERTY D, HEUVELMANS H et al.: Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull. World Health Organ. (2001) 79:388-393.
16. ROBERTS WL, MCMURRAY WJ, RAINEY PM: Characterization of the antimonial antileishmanial agent meglumine antimonate (Glucantime). Antimicrob. Agents Chemother. (1998) 42:1076-1082.
17. PATHAK MK, YI T: Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. (2001) 167:3391-3397.
18. THAKUR CP, SINGH RK, HASSAN SM, KUMAR R, NARAIN S, KUMAR A: Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans. R. Soc. Trop. Med. Hyg. (1999) 93:319-323.
19. CROFT SL, URBINA JA, BRUN R: Chemotherapy of human leishmaniasis and trypanosomiasis. In: Trypanosomiasis and Leishmaniasis. Hide G, Mottram JC, Commbs GB, Holmes PH (Eds), CAB International, London, UK (1997): 245-257.
20. BERMAN JD: Editorial Response: US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis. (1999) 28:49-51.
21. MURRAY HW: Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. (2001) 45:2185-2197.
22. BERMAN JD, BADARO R, THAKUR CP et al.: Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. World Health Organ. (1998) 76:25-32.
23. MEYERHOFF A: US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis. (1999) 28:49-51.
24. YARDLEY V, CROFT SL: A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int. J. Antimicrob. Agents. (2000) 13:243-248.
25. PIÑERO JE, MARTINEZ S, DEL CASTILLO A, PORTUS M, VALLADARES B: In vitro susceptibility of Leishmania infantum strains isolated from Spanish HIV-positive patients to Abelcet and Fungizone. J. Antimicrob. Chemother. (2002) 50:304-306.
26. SUNDAR S, MEHTA H, SURESH AV, SINGH SP, RAI M, MURRAY HW: Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin. Infect. Dis. (2004) 38:377-383.
27. MURRAY HW, BROOKS EB, DEVECCHIO JL, HEINZEL FP: Immuno enhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob. Agents Chemother. (2003) 47:2513-2517.
28. CROFT SL, NEAL RA, PENDERGAST W, CHAN JH: The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol. (1987) 36:2633-2636.
29. KUHLENCORD A, MANIERA T, EIBL H, UNGER C: Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. (1992) 36:1630-1634.
30. LE FICHOUX Y, ROUSSEAU D, FERRUA B et al.: Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob. Agents Chemother. (1998) 42:654-658.
31. CROFT SL, SNOWDON D, YARDLEY V: The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. (1996) 38:1041-1047.
32. CROFT SL, SEIFERT K, DUCHENE M: Antiprotozoal activities of phospholipid analogues. Mol. Biochem. Parasitol. (2003) 126:165-172.
33. LUX H, HART DT, PARKER PJ, KLENNER T: Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. Adv. Exp. Med. Biol. (1996) 416:201-211.
34. LUX H, HEISE N, KLENNER T, HART D, OPPERDOES FR: Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol. (2000) 111:1-14.
35. PARIS C, LOISEAU PM, BORIES C, BREARD J: Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. (2004) 48:852-859.
36. SUNDAR S, ROSENKAIMER F, MAKHARIA MK et al.: Trial of oral miltefosine for visceral leishmaniasis. Lancet (1998) 352:1821-1823.
37. SUNDAR S, JHA TK, THAKUR CP et al.: Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. (2002) 347:1739-1746.
38. PRASAD R, KUMAR R, JAISWAL EP, SINGH UK: Miltefosine: an oral drug for visceral leishmaniasis. Indian J. Pediatr. (2004) 71:143-144.
39. BHATTACHARYA SK, JHA TK, SUNDAR S et al.: Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin. Infect. Dis. (2004) 38:217-221.
40. SOTO J, TOLEDO J, GUTIERREZ P et al.: Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. (2001) 33:57-61.
41. SOTO J, ARANA BA, TOLEDO J et al.: Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. (2004) 38:1266-1272.
42. 3 (edelfosine) and amphotericin B. Acta Trop. (2002) 81:151-157.
43. PEREZ-VICTORIA JM, PEREZ-VICTORIA FJ, PARODI-TALICE A et al.: Alkyllysophospholipid resistance in multidrug resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob. Agents Chemother. (2001) 45:2468-2474.
44. SHERWOOD JA, GACHIHI GS, MUIGAI RK et al.: Phase II efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin. Infect. Dis. (1994) 19:1034-1039.
45. DIETZE R, CARVALHO SF, VALLI LC et al.: Phase II trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am. J. Trop. Med. Hyg. (2001) 65:685-689.
46. MBUI J, RASHID R, LODENYO H et al.: Visceral leishmaniasis with concomittant post kala-azar dermal leishmaniasis responds to oral sitamaquine: case report. East Afr. Med. J. (2003) 80:440-442.
47. THAKUR CP, KANYOK TP, PANDEY AK, SINHA GP, MESSICK C, OLLIARO P: Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized Phase-II clinical study. Trans. R. Soc. Trop. Med. Hyg. (2000) 94:432-433.
48. KAGER PA, REES PH, WELLDE BT, HOCKMEYER WT, LYVERLY WH: Allopurinol in the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (1981) 75:556-559.
49. CHUNGE CN, GACHIHI G, MUIGAI R: Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans. R. Soc. Trop. Med. Hyg. (1985) 79:715-718.
50. JHA TK. Evaluation of allopurinol in the treatment of kala-azar occurring in North Bihar, India. Trans. R. Soc. Trop. Med. Hyg. (1983) 77:204-207.
51. RAGUSA R, DI CATALDO A, SAMPERI P, SCHILIRO G: Treatment of visceral leishmaniasis with meglumine and allopurinol. Am. J. Dis. Child. (1993) 147:611-612.
52. DAS VN, RANJAN A, SINHA AN et al.: A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J. Assoc. Physicians India (2001) 49:609-613.
53. RODRIGUEZ N, BAILEY BN, MARTIN MB, OLDFIEL E, URBINA JA, DOCAMPO R: Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J. Infect. Dis. (2002) 186:138-140.
54. DOCAMPO R, MORENO SN: Bisphosphonates as chemotherapeutic agents against trypanosomatid and apicomplexan parasites. Curr. Drug Targets Infect. Disord. (2001) 1:51-61.
55. AKENDENGUE B, NGOU-MILAMA E, LAURENS A, HOCQUEMILLER R: Recent advances in the fight against leishmaniasis with natural products. Parasite (1999) 6:3-8.
56. CHAN-BACAB MJ, PENA-RODRIGUEZ LM: Plant natural products with leishmanicidal activity. Nat. Prod. Rep. (2001) 18:674-688.
57. FOURNET A, MUNOZ V: Natural products as trypanocidal, antileishmanial and antimalarial drugs. Curr. Top. Med. Chem. (2002) 2:1215-1237.
58. NIELSEN SF, CHRISTENSEN SB, CRUCIANI G, KHARAZMI A, LILJEFORS T: Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. J. Med. Chem. (1998) 41:4819-4832.
59. KAYSER O, KIDERLEN AF: In vitro leishmanicidal activity of naturally occurring chalcones. Phytother. Res. (2001) 15:148-152.
60. HERMOSO A, JIMENEZ IA, MAMANI ZA et al.: Antileishmanial activities of dihydrochalcones from Piper elongatum and synthetic related compounds. Structural requirements for activity. Bioorg. Med. Chem. (2003) 11:3975-3980.
61. CHEN M, ZHAI L, CHRISTENSEN SB, THEANDER TG, KHARAZMI A: Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones. Antimicrob. Agents Chemother. (2001) 45:2023-2029.
62. FOURNET A, FERREIRA ME, ROJAS DE ARIAS A et al.: In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrob. Agents Chemother. (1996) 40:2447-2451.
63. MEDDA S, MUKHOPADHYAY S, BASU MK: Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J. Antimicrob. Chemother. (1999) 44:791-794.
64. MAES L, VANDEN BERGHE D, GERMONPREZ N et al.: In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species. Antimicrob. Agents Chemother. (2004) 48:130-136.
65. LUQUE-ORTEGA JR, MARTINEZ S, SAUGAR JM et al.: Fungus-elicited metabolites from plants as an enriched source for new leishmanicidal agents: antifungal phenyl-phenalenone phytoalexins from the banana plant (Musa acuminata) target mitochondria of Leishmania donovani promastigotes. Antimicrob. Agents Chemother. (2004) 48:1534-1540.
66. MURRAY HW, GRANGER AM, MOHANTY SK: Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma and interleukin-2-independent. J. Infect. Dis. (1991) 163:622-624.
67. BADARO,R, FALCOFF E, BADARO FS et al.: Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N. Engl. J. Med. (1990) 322:16-21.
68. SUNDAR S, SINGH VP, SHARMA S, MAKHARIA MK, MURRAY HW: Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J. Infect. Dis. (1997) 176:1117-1119.
69. HARRISON CJ, MILLER RL, BERNSTEIN DI: Post-therapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob. Agents Chemother. (1994) 38:2059-2064.
70. TESTERMAN TL, GERSTER JF, IMBERTSON LM et al.: Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leukoc. Biol. (1995) 58:365-372.
71. BUATES S, MATLASHEWSKI G: Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect. Dis. (1999) 179:1485-1494.
72. AREVALO I, WARD B, MILLER R et al.: Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. (2001) 33:1847-1851.
73. SELZER PM, CHEN X, CHAN VJ et al.: Leishmania major: molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors. Exp. Parasitol. (1997) 87:212-221.
74. MOTTRAM JC, BROOKS DR, COOMBS GH: Roles of cysteine proteinases of trypanosomes and Leishmania in host-parasite interactions. Curr. Opin. Microbiol. (1998) 1:455-460.
75. MCKERROW JH: Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Int. J. Parasitol. (1999) 29:833-837.
76. MCKERROW JH, ENGEL JC, CAFFREY CR: Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg. Med. Chem. (1999) 7:639-644.
77. SALVATI L, MATTU M, COLASANTI M et al.: NO donors inhibit Leishmania infantum cysteine proteinase activity. Biochim. Biophys. Acta (2001) 1545:357-366.
78. ZEINA B, BANFIELD C, AL-ASSAD S: Topical glyceryl trinitrate: a possible treatment for cutaneous leishmaniasis. Clin. Exp. Dermatol. (1997) 22:244-245.
79. LOPEZ-JARAMILLO P, RUANO C, RIVERA J et al.: Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet (1998) 351:1176-1177.
80. DAVIDSON RN, YARDLEY V, CROFT SL, KONECNY P, BENJAMIN N: A topical nitric oxide-generating therapy for cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (2000) 94:319-322.
81. BOCEDI A, GRADONI L, MENEGATTI E, ASCENZI P: Kinetics of parasite cysteine proteinase inactivation by NO-donors. Biochem. Biophy. Res. Commun. (2004) 315:710-718.
82. JUNGHAE M, RAYNES JG: Activation of p38 mitogen-activated protein kinase attenuates Leishmania donovani infection in macrophages. Infect. Immun. (2002) 70:5026-5035.
83. AWASTHI A, MATHUR R, KHAN A et al.: CD40 signalling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. J. Exp. Med. (2003) 197:1037-1043.
84. YEATES C: Sitamaquine GlaxoSmithKline/Walter Reed Army Institute. Curr. Opin. Investig. Drugs (2002) 3(10):1446-1452.
85. SUNDAR S, RAI M: Advances in the treatment of leishmaniasis. Current Opinion in Infectious Diseases. (2002) 15(6):593-598.
86. MARTY P, ROSENTHAL E: Treatment of visceral leishmaniasis: a review of current treatment practices. Expert Opin. Pharmacother. (2002) 3(8):1101-1108.
87. KAMINSKY R: Miltefosine Zentaris. Curr. Opin. Investig. Drugs (2002) 3(4):50-54.
88. CROFT SL, YARDLEY V: Chemotherapy of leishmaniasis. Curr. Pharm. Des. (2002) 8:319-342.
89. CROFT SL, COOMBS GH: Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. (2003) 19:502-508.